Loading quotes...
Forecast
The analysts' average price target is 57,07⏠(+42,07%). The median is 54,50⏠(+35,67%).
| Buy |
Â
38 |
| Hold |
Â
6 |
| Sell |
Â
0 |
News Go to news feed
Boston Scientific's supply chain disrupted worldwide by cyberattack
Boston Scientific reports a cyberattack discovered on August 25 that has affected information systems and business applications, causing disruptions to order processing and shipping worldwide. Employees at one site in Ireland were sent home. The company has brought in external cybersecurity experts and is working on restoration, but cannot say when full operations will resume; the extent of operational and financial damage remains unclear. » More on golem.de
Boston Scientific cyberattack disrupts global operations and order processing
Boston Scientific said a cyberattack uncovered Tuesday is disrupting its global information systems and business applications, including systems used to process and ship customer orders. The company has engaged outside cybersecurity experts to investigate and contain the threat while working to restore affected functions, but a full recovery timeline is unknown. Shares fell as much as 6% in early trading following the disclosure. » More on cbsnews.com
Boston Scientific weighed by weaker Watchman results and lowered 2026 guidance
Boston Scientific's shares fell after Q2 results as U.S. Electrophysiology and Watchman missed consensus and management cut 2026 organic sales growth guidance to 10â11%. CHAMPION-AF data met endpoints but failed to act as a positive catalyst for the stock. TCW said the market may be overly discounting Boston Scientific's long-term earnings growth, but the position remains under review. » More on finance.yahoo.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 4,77B | 11,05% |
| Gross profit | 3,37B | 16,06% |
| Net profit | 794,72M | 18,12% |
| EBITDA | 1,22B | 4,94% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 61,45B⏠|
Number of shares | 1,49B |
52-week high/low | 93,97⏠- 36,22⏠|
| Dividends | No |
Beta | 0,57 |
P/E ratio | 19,42 |
PEG ratio | 0,42 |
P/B ratio | 2,86 |
P/S ratio | 3,41 |
Company profile
Die Boston Scientific Corporation entwickelt, produziert und vertreibt weltweit medizinische GerĂ€te fĂŒr den Einsatz in verschiedenen interventionellen medizinischen Fachgebieten. Das Unternehmen ist in drei Segmenten tĂ€tig: MedSurg, Rhythm and Neuro, und Cardiovascular. Das Unternehmen bietet GerĂ€te zur Diagnose und Behandlung von Magen-Darm- und Lungenerkrankungen, GerĂ€te zur Behandlung verschiedener urologischer und pelviner Erkrankungen, implantierbare Kardioverter und implantierbare Herz-Resynchronisations-Therapie-Defibrillatoren, Herzschrittmacher und implantierbare Herz-Resynchronisations-Therapie-Schrittmacher sowie Remote-Patienten-Management-Systeme. DarĂŒber hinaus bietet das Unternehmen Medizintechnologien zur Diagnose und Behandlung von Herzrhythmusstörungen an, darunter 3D-Kardio-Mapping- und Navigationslösungen, Ablationskatheter, Diagnosekatheter, Mapping-Katheter, intrakardiale Ultraschallkatheter, EinfĂŒhrschleusen und anderes Zubehör, RĂŒckenmarkstimulatorsysteme fĂŒr die Behandlung chronischer Schmerzen, indirekte Dekompressionssysteme und Systeme zur Tiefenhirnstimulation. DarĂŒber hinaus bietet das Unternehmen Produkte fĂŒr die interventionelle Kardiologie an, darunter medikamentenfreisetzende Koronarstentsysteme zur Behandlung der Koronararterienerkrankung, Produkte fĂŒr die perkutane Koronarintervention zur Behandlung von Atherosklerose, Katheter fĂŒr die intravaskulĂ€re Ultraschallbildgebung, GerĂ€te fĂŒr die fraktionierte Flussreserve und Systeme fĂŒr den Einsatz in Koronararterien und Herzkammern sowie in verschiedenen peripheren GefĂ€Ăen und strukturelle Herztherapien. DarĂŒber hinaus bietet das Unternehmen Stents, Ballonkatheter, DrĂ€hte und Atherektomiesysteme zur Behandlung von Arterienerkrankungen, Thrombektomie- und akustische Impulsthrombolysesysteme, DrĂ€hte und Stents zur Behandlung von Venenerkrankungen sowie periphere EmbolisationsgerĂ€te, radioaktive MikrosphĂ€ren, Ablationssysteme, Kryotherapie-Ablationssysteme und Mikro- und Drainagekatheter zur Behandlung von Krebs. Das Unternehmen wurde 1979 gegrĂŒndet und hat seinen Hauptsitz in Marlborough, Massachusetts.
| Name | Boston Scientific |
| CEO | Michael F. Mahoney |
| Headquarters | Marlborough,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 11/19/2019 |
| Employees | 59.000 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | BSX |
London Stock Exchange | 0HOY.L |
XETRA | BSX.F |
Frankfurt | BSX.F |
DĂŒsseldorf | BSX.DU |
Milan | 1BSX.MI |
London | 0HOY.L |
SIX | BSX.SW |
MĂŒnchen | BSX.MU |
Wien | BSXC.VI |
Discover assets
Shareholders of Boston Scientific also invest in the following assets
